Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

Eris Lifesciences Limited's revenue projections indicate a decrease from last year's performance, which could lead to investor caution. A fall in revenue is likely to negatively impact the company's profitability, causing concern for shareholders who may view this as a signal of declining financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 26.271906
debtToEquity 68.185000
earningsGrowth 0.191000
revenueGrowth 0.109000
grossMargins 0.739070
operatingMargins 0.263790
trailingEps 31.490000
forwardEps 50.281850

Eris Lifesciences Limited's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
Eris Lifesciences Limited's positive earnings and revenue growth signal that the company is expected to expand its business. This healthy financial trend reflects an optimistic outlook, suggesting continued growth in both sales and profits for Eris Lifesciences Limited.
ERIS's positive gross and operating margins reflect strong profitability and operational efficiency. These metrics indicate the company's ability to control costs while maintaining healthy revenue, contributing to its solid financial performance.
Eris Lifesciences Limited's forward EPS exceeding its trailing EPS implies that the company is projected to be more profitable this year. This suggests an improvement in financial performance, with analysts expecting Eris Lifesciences Limited to generate stronger earnings compared to the previous financial year.

Price projections:

Price projections for ERIS
Price projections for ERIS

The price of ERIS currently does not indicate any clear risks or opportunities when compared to projections. This balanced stance suggests that investors may prefer to hold off on major decisions until new information arises.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


Analysts' buy bias for ERIS signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to ERIS, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.